Major Shareholder Announcement

Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, has decreased its holding of B shares in Novozymes to 7.64%, previously reported at 7.82% (a decrease of 0.18%).

12. September 2012
In accordance with section 29 of the Danish Securities Trading Act, Novozymes hereby announces that it has been informed that Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, has decreased its holding of B shares in Novozymes to 7.64%, previously reported at 7.82% (a decrease of 0.18%).

 

Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, now holds B shares in Novozymes A/S to a total of 24,845,307 shares of a nominal value of DKK 49,690,614, equivalent to 7.64% of Novozymes A/S’ share capital and 3.07% of the voting rights. The announcement is a result of Baillie Gifford Overseas Limited, a wholly owned subsidiary of Baillie Gifford & Co, decreasing its holding of B shares in Novozymes A/S to a total of 16,235,029 B shares of a nominal value of DKK 32,470,058, equivalent to 4.995% of Novozymes share capital.
 
Contact persons:
Press and media:
Investor relations:
René Tronborg (Europe)
Tel. (direct): +45 4446 2274
Tel. (mobile): +45 3077 2274
 
Paige Donnelly (USA)
Tel. (direct): +1 919 494 3209
Tel. (mobile): +1 919 218 4501
Maarit Pokkinen
Tel. (direct): +45 4446 8682
Tel. (mobile): +45 3077 8682
 
Martin Riise
Tel. (direct): +45 4446 0738
Tel. (mobile): +45 3077 0738
 
Thomas Bomhoff (USA)
Tel. (direct): +1 919 494 3483
Tel. (mobile):  +1 919 649 2565